Hypoglycemic Agents

ApprovedSmall molecule

SScotmann Pharmaceuticals

Hypoglycemic Agents is one of 138 small molecule programs targeting Peripheral Neuropathy. It is currently in Approved.

Indications

Total Trials

Active Trials

137

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peripheral NeuropathyActive, not recruiting

Diabetes MellitusActive, not recruiting

Type 2 DiabetesActive, not recruiting

Diabetic RetinopathyActive, not recruiting

Peripheral NeuropathyApproved

Active, not recruiting

Diabetes MellitusPhase 3

Active, not recruiting

Type 2 DiabetesPhase 2/Phase 3

Active, not recruiting

Diabetic RetinopathyPhase 3

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Hypoglycemic Agents

SScotmann Pharmaceuticals

Approved

1 2

Byetta

AstraZeneca

Preclinical

55 3

Jardiance

Boehringer Ingelheim

Preclinical

31 4

NOVOLIN R

Novo Nordisk

Preclinical

5 5

Glargine

Eli Lilly

Preclinical

8 6

Aurlumyn

BBTG International Inc.

Preclinical

1 7

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

1 8

Forxiga

AstraZeneca

Preclinical

3 9

Lovaza

AstraZeneca

Preclinical

1 10

Acipimox

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diabetic Retinopathy1 trial

Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00542178·3,472 enrolled

Diabetes1 trial

Clinical Evaluation of Fenugreek Seed Extract, a Nutraceutical in Patients With Type- 2 Diabetes

Completed·—·N/A·NCT02693392·200 enrolled

Prevention1 trial

Prevention of Instent Renarrowing With Aggressive Glucose Lowering With Pioglitazone in Diabetic Patients

Completed·QQueen Elizabeth II Health Sciences Centre·Phase 4·NCT00819325·50 enrolled

Peripheral Neuropathy1 trial

The Effect of Related Blood Markers on Diabetic Peripheral Neuropathy

Unknown status·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 4·NCT06041399·1,400 enrolled

Diabetes Mellitus1 trial

Vitamin D, K2 Plus Empagliflozin Combination in Type Two Diabetes Mellitus

Unknown status·SScotmann Pharmaceuticals·Phase 3·NCT05417880·340 enrolled

1 more indication

Type 2 Diabetes1 trial

Effect of Folic Acid and Vitamin B12 Supplementation in Subjects With Type 2 Diabetes

Completed·—·Phase 2/3·NCT02786823·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Hypoglycemic Agents. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hypoglycemic Agents compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hypoglycemic Agents. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Scotmann Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SScotmann Pharmaceuticals

Hypoglycemic Agents

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Diabetic Retinopathy1 trial

Diabetes1 trial

Prevention1 trial

Peripheral Neuropathy1 trial

Diabetes Mellitus1 trial

Type 2 Diabetes1 trial

References

Drug Info

Quick Facts

Related News